Sapience Therapeutics Inc.
Harrison, NY · Founded 2015 · CIK 0001661731 · Biotech · Private
Peptide therapeutics for oncology targeting previously undruggable cancer proteins
sapiencetherapeutics.com →- Grants
- $6.6M
- 10 awards
- Sector median: 1
- Raised
- $8.3M
- 3 Form D · Jul 2020
- 75 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 37
- 5 granted · 32 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $300,000 | |
| Private capital raised | Form D · SEC | $22,500,000 | |
| Private capital raised | Form D · SEC | $8,010,876 | |
| Federal grant | Department of Health and Human Services · Phase I · Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer | $255,240 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | $588,038 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | $299,860 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $409,295 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | $288,178 | |
| Federal grant | Department of Health and Human Services · Phase II · Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer | $631,607 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $1,362,268 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $1,362,268 | |
| Federal grant | Department of Health and Human Services · Phase II · Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer | $803,479 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $632,111 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1808 | Future Path Medical Holding Company, LLC | — | $2.6M |
| 1809 | ImmunityBio, Inc. | — | $633M |
| 1810 | MODERN MEADOW | — | $53M |
| 1811 | Sapience Therapeutics Inc. | — | $8.3M |
| 1812 | Marius Pharmaceuticals, LLC | — | $5.6M |
| 1813 | MDI Therapeutics Investors, LLC | — | — |
| 1814 | Rectify | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Isaac BlechDirector
- Barry KappelDirector · Executive Officer
- Barry Kappel, Ph.D.Director · Executive Officer
- Howard PienDirector
- Robert RuffoloDirector
- Robert Ruffolo, Ph.D.Director
- Christian SchadeDirector
- David ScheinbergDirector
- David Scheinberg, Ph.D.Director
Patents
- Modified BCL9 Mimetic Peptidesgranted
- ATF5 Peptide Variants and Uses Thereofapplication
- ATF5 Peptide Variants and Uses Thereofgranted
- ATF5 Peptide Variants and Uses Thereofgranted
- Administration of CEBP-Beta Antagonist and Methods of Useapplication
- ATF5 Peptide Variants and Uses Thereofgranted
- Cell-Penetrating ATF5 Polypeptides and Uses Thereofgranted
- Administration of a Beta-Catenin Antagonist and Methods of Useapplication
- Use of Beta-Catenin Antagonist and Immunomodulatorapplication
- Methods Of Treating Or Preventing Infusion-related Reactionsapplication
- Use of C/EBP-Beta Antagonist and Immunomodulatorapplication
- Methods of Treating or Preventing Infusion-Related Reactionsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.